男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Everest Medicine's mRNA production base commences operations

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2023-03-01 21:18
Share
Share - WeChat
The mRNA vaccine industrialization base of Everest Medicines in Jiashan, Zhejiang province. [Photo provided to chinadaily.com.cn]

Everest Medicines, a Hong Kong-listed Chinese biopharmaceutical company, announced the official opening of its messenger RNA vaccine industrialization base in Jiashan, Zhejiang province, on Tuesday.

With a focus on innovative medicines and the discovery, development, and commercialization of mRNA vaccines, the company said the annual production capacity from the base is expected to reach 700 million doses.

Boasting an investment scale of more than 900 million yuan ($130 million), the base covers an area of nearly 57,000 square meters and is equipped with a complete set of advanced production facilities and quality assurance systems.

Everest said the base launched trial production in December and has proven capable of large-scale production of mRNA vaccines. Data from tests showed the manufacturing process and finished products met expected parameters.

Due to the COVID-19 pandemic and a surge in demand for related vaccines, mRNA technology has received extensive attention and accelerated research. It has shown broad application potential and clinical value in the prevention and treatment of deadly diseases such as cancer and many contagions.

"We'll continue to accelerate clinical trials of related products and strive to realize their commercialization as soon as possible to meet the urgent demand for advanced mRNA vaccines in Greater China, Asia and the world," Everest CEO Luo Yongqing said.

The company has announced its formulation of a candidate COVID-19 vaccine, with clinical trials scheduled to kick off in China this year.

In addition, the company said it is exploring the potential of mRNA technology and will develop new preventive and therapeutic vaccines for infectious diseases and tumors.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亳州市| 宁明县| 宿松县| 怀集县| 海晏县| 全州县| 睢宁县| 通海县| 德庆县| 高平市| 蓬莱市| 富顺县| 吉木乃县| 林西县| 乌拉特中旗| 普宁市| 涿鹿县| 新昌县| 固安县| 桂东县| 肇东市| 芷江| 镇平县| 乌海市| 公安县| 自治县| 克拉玛依市| 太仓市| 阜阳市| 徐闻县| 罗源县| 漠河县| 日土县| 砀山县| 衡阳县| 洱源县| 平远县| 丹江口市| 澄城县| 凤山市| 巴楚县|